Multi-isotope calibration (MICal) is a novel approach to calibration for inductively coupled plasma mass spectrometry (ICP-MS). In MICal, only two calibration solutions are required: solution A, composed of 50% v v of sample and 50% v v of a standard solution containing the analytes, and solution B, composed of 50% v v of sample and 50% v v of a blank solution. MICal is based on monitoring the signal intensities of several isotopes of the same analyte in solutions A and B. By plotting the analytical signals from solution A in the x-axis, and from solution B in the y-axis, the analyte concentration in the sample is calculated using the slope of that graph and the concentration of the reference standard added to solution A. As both solutions contain the same amount of sample, matrix-matching is easily achieved. In this proof-of-concept study, MICal was applied to the determination of Ba, Cd, Se, Sn, and Zn in seven certified reference materials with different matrices (e.g., plant materials, flours, and water). In most cases, MICal results presented no statistical difference from the certified values at a 95% confidence level. The new strategy was also compared with traditional calibration methods such as external calibration, internal standardization and standard additions, and recoveries were generally better for MICal. This is a simple, accurate, and fast alternative method for matrix-matching calibration in ICP-MS. Graphical abstract Multi-isotope calibration: fast and innovative matrix-matching calibration for ICP-MS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00216-017-0753-4 | DOI Listing |
BMC Ophthalmol
July 2024
Department of Ophthalmology, The David J Apple Center for Vision Research, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
J Osteopath Med
March 2024
Division of Rheumatology, Nova Southeastern University, Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, FL, USA.
Context: Cardiovascular disease (CVD) is the leading cause of death in the United States. As such, an unmet need exists in the primary and secondary prevention of adverse cardiovascular events (CVEs). Specifically, identifying drugs that can reduce the progression of CVD and serious adverse events is much needed.
View Article and Find Full Text PDFTH Open
October 2022
Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, United States.
Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these events. This analysis was designed to describe patient characteristics, medication use, thromboembolic events, and all-cause mortality in hospitalized COVID-19 patients in the United States.
View Article and Find Full Text PDFPacing Clin Electrophysiol
July 2022
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Introduction: The electrophysiological discrimination between fast-slow (F/S-) atrioventricular (AV) nodal reentrant tachycardia (NRT) and atrial tachycardia (AT) originating from the interatrial septum remains challenging. While a V-A-A-V response may occur immediately after ventricular induction or entrainment of either tachycardia, the electrophysiological dissimilarities in that response between the two tachycardias remain unclear. The purpose of this study was to identify a diagnostic indicator discriminating F/S-AVNRT from AT by examining the difference in the V-A-A-V response between the two tachycardias.
View Article and Find Full Text PDFNat Commun
December 2021
Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated with 2 doses (in weeks 1 and 3) of immune checkpoint blockade (ICB) using nivolumab (NIVO MONO, n = 6, phase Ib arm A) or nivolumab plus a single dose of ipilimumab (COMBO, n = 26, 6 in phase Ib arm B, and 20 in phase IIa) prior to surgery. Primary endpoints are feasibility to resect no later than week 6 (phase Ib) and primary tumor pathological response (phase IIa).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!